ELINEST Drug Patent Profile
✉ Email this page to a colleague
When do Elinest patents expire, and when can generic versions of Elinest launch?
Elinest is a drug marketed by Novast Labs Ltd and is included in one NDA.
The generic ingredient in ELINEST is ethinyl estradiol; norgestrel. There are twenty-six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestrel profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ELINEST?
- What are the global sales for ELINEST?
- What is Average Wholesale Price for ELINEST?
Summary for ELINEST
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Sales Revenues: | Drug sales revenues for ELINEST |
| DailyMed Link: | ELINEST at DailyMed |
US Patents and Regulatory Information for ELINEST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novast Labs Ltd | ELINEST | ethinyl estradiol; norgestrel | TABLET;ORAL-28 | 091105-001 | Mar 28, 2012 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
